Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Goserelin Acetate

FDA-approved product (implant, implantation), marketed as Zoladex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Goserelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Goserelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Goserelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

    NCT00186121 · start 2000-10

    Registered record
    Registry ID
    NCT00186121
    Conditions
    Breast Cancer
    Interventions
    Anastrozole (Arimidex); Goserelin (Zoladex)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-10
    Completion
    2013-06
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAnastrozole (Arimidex); Goserelin (Zoladex)
    PhasePhase 2
    Registry statusCompleted

  • Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer

    NCT00031850 · start 2000-03

    Registered record
    Registry ID
    NCT00031850
    Conditions
    Breast Cancer
    Interventions
    goserelin acetate; raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-03
    Completion
    2007-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiongoserelin acetate; raloxifene
    PhaseNot applicable
    Registry statusCompleted

  • Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

    NCT00841113 · start 1999-01

    Registered record
    Registry ID
    NCT00841113
    Conditions
    Prostate Cancer
    Interventions
    Abarelix; Goserelin plus Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-01
    Completion
    2003-02
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbarelix; Goserelin plus Bicalutamide
    PhasePhase 3
    Registry statusCompleted

  • Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

    NCT00309478 · start 1990-12

    Registered record
    Registry ID
    NCT00309478
    Conditions
    Early-stage Breast Cancer
    Interventions
    Cyclophosphamide; Methotrexate; Fluorouracil implant; Goserelin; Tamoxifen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1990-12
    Completion
    2004-06
    Enrolment
    1,099

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-stage Breast Cancer
    InterventionCyclophosphamide; Methotrexate; Fluorouracil implant; Goserelin +1 more
    PhasePhase 3
    Registry statusCompleted

  • MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

    NCT01240928

    Registered record
    Registry ID
    NCT01240928
    Conditions
    Metastatic Breast Cancer
    Interventions
    MSK-2206; Exemestane; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionMSK-2206; Exemestane; Goserelin
    PhasePhase 1
    Registry statusWithdrawn